−Removed: Below is a summary of our leased properties as of December 31, 2020:
−Removed: We lease approximately 29,000 square feet of combined laboratory and office space in Pittsburgh, Pennsylvania that we use for our research, development and manufacturing efforts.
−Removed: This lease expires in February 2027.
−Removed: On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility in the Pittsburgh, Pennsylvania area.
−Removed: The 150,000 square foot facility is under construction and is expected to be completed and validated in 2022.
−Removed: The lease commenced on February 1, 2021 when the Landlord delivered the space as substantially complete and made the space available for access by the Company.
−Removed: The lease has an initial term that expires on October 31, 2035 .
+Added: As of December 31, 2021, we lease approximately 44,000 square feet of combined laboratory and office space in Pittsburgh, Pennsylvania that we use for our research, development and manufacturing efforts.
+Added: This lease expires in October 2031.
+Added: On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area, which contained an option to purchase the building.
+Added: On January 29, 2021, we entered into a Purchase and Sale Agreement with Northfield I, LLC, an Ohio limited liability company to acquire ASTRA, and the related purchase closed on March 5, 2021.
+Added: On June 30, 2021, we entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction with The Whiting-Turner Contracting Company (“Whiting-Turner”), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA.
+Added: The facility is under construction and expected to be completed and validated in 2022.
+Added: Refer to Note 6 of the Notes to the Consolidated Financial Statements included in Part II of Item 8 of this Annual Report on Form 10-K for more information regarding this transaction.
+Added: Legal Proceedings.
+Added: The information set forth in Note 6 of the Notes to the Consolidated Financial Statements included in Part II Item 8 of this Annual Report on Form 10-K is incorporated by reference into this Item 3.
+Added: Mine Safety Disclosures.
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.